University of Michigan

Jianfeng Lu

Shaomeng Wang

Haiying Sun

Liu Liu

Zaneta Nikolovska-Coleska

Su Qiu

Yuefeng Peng

Qian Cai

Donna McEachern

Jeanne Stuckey

Dongguang Qin

Haibin Zhou

Yi Sun

Ester Fernandez-Salas

Chao-Yie Yang

Angelo Aguilar

Denzil Bernard

Rohan Rej

Liangyou Rui

Rong Sheng

Mi Wang

Changwei Wang

Donna Mceachern

The present disclosure provides compounds represented by Formula I: wherein R, R, R, and Rare as defined in the specification, and the salts and solvates thereof. Compounds of Formula I are EED inhibitors. EED inhibitors are useful for the treatment of cancer and other diseases.

Imidazopyrimidines as EED inhibitors and the use thereof

Compounds of formula (I) as inhibitors of DCN1 and compositions containing the same are disclosed. Methods of using the DCN1 inhibitors in the treatment of diseases and conditions wherein inhibition of DCN1 provides a benefit, like oxidative stress-related diseases and conditions, neurodegenerative diseases and conditions, metabolic disorders, and muscular nerve degeneration, also are disclosed.

Small molecule DCN1 inhibitors and therapeutic methods using the same

Small molecule covalent inhibitors of DCN1 and compositions containing the same are disclosed. Methods of using the DCN1 covalent inhibitors in the treatment of diseases and conditions wherein inhibition of DCN1 provides a benefit, like oxidative stress-related diseases and conditions, neurodegenerative diseases and conditions, metabolic disorders, and muscular nerve degeneration, also are disclosed.

Covalent small molecule DCN1 inhibitors and therapeutic methods using the same

Inhibitors of MDM2 and MDM2-related proteins and compositions containing the same are disclosed. Methods of using the MDM2 inhibitors in the treatment of diseases and conditions wherein inhibition of an interaction between p53 and MDM2 provides a benefit, like cancers, also are disclosed.

MDM2 inhibitors and therapeutic methods using the same

Inhibitors of IAP proteins and compositions containing the same are disclosed. Methods of using the IAP protein inhibitors in the treatment of diseases and conditions wherein inhibition of IAP proteins provides a benefit, like cancers, also are disclosed.

Bivalent inhibitors of IAP proteins and therapeutic methods using the same

The invention relates to diazo bicyclic mimetics of Smac which function as inhibitors of Inhibitor of Apoptosis Proteins. The invention also relates to the use of these mimetics for inducing apoptotic cell death and for sensitizing cells to inducers of apoptosis.

Diazo bicyclic Smac mimetics and the uses thereof

The invention relates to bivalent mimetics of Smac which function as inhibitors of Inhibitor of Apoptosis Proteins. The invention also relates to the use of these mimetics for inducing apoptotic cell death and for sensitizing cells to inducers of apoptosis.

Bivalent SMAC mimetics and the uses thereof

Bivalent Smac mimetics and the uses thereof

Growing community of inventors

Ann Arbor, MI, United States of America

Jianfeng Lu